A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Pumitamig
DRUG: Ipilimumab
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]